Skip to main content
Market Trend6 min read

Immunology Deals Up 1167% in 2026 — Here's the Data

Immunology deal activity jumped from 3 transactions to 38 in just six months — a 1167% increase that signals a fundamental shift in Big Pharma portfolio strategy. We break down the deals, the drivers, and what BD teams should do right now.

AV
Ambrosia Ventures
·Based on 1,400+ transactions

Immunology deal activity surged 1167% in the six months ending November 10, 2026, with 38 transactions recorded versus just 3 in the prior half-year (November 10, 2025 to May 10, 2026). This is not a statistical blip — it is the sharpest therapeutic-area acceleration we have tracked this year, and it reflects a convergence of Big Pharma pipeline anxiety, next-generation mechanism validation, and aggressive cross-border licensing that is redrawing the immunology competitive map.

The Data — Immunology Deal Activity, Period over Period

PeriodValue
2025-11-10 to 2026-05-103
2026-05-10 to 2026-11-1038
Change+1167.0%

Three deals in six months is trough-level activity for a therapeutic area that generates over $120B in annual global sales. Thirty-eight deals in the subsequent half-year is a market catching its breath and then sprinting. The inflection point landed squarely in Q3 2026 — the quarter that produced four of the five largest transactions in this dataset.

What's Driving the Trend

Pipeline replacement urgency is the primary catalyst. The immunology franchise pillars — adalimumab, ustekinumab, risankizumab — are either already facing biosimilar erosion or approaching LOE cliffs between 2027 and 2030. AstraZeneca's $200M upfront / $2.1B TDV deal with Sino Biopharmaceutical is a textbook example: a top-10 pharma backfilling its autoimmune portfolio by sourcing differentiated assets from China-based innovators rather than waiting on internal discovery timelines. The economics of internal R&D simply cannot match the speed-to-clinic that licensing provides when the revenue cliff is 18–36 months away.

Mechanism-of-action diversification is accelerating. The immunology licensing 2026 cohort is not dominated by another wave of IL-17 or IL-23 antibodies. Deal flow shows pronounced interest in novel targets — TL1A, OX40L, CD40L, and bispecific formats that combine cytokine blockade with tissue-homing — reflecting a market consensus that next-gen immunology drugs must demonstrate differentiation beyond incremental efficacy gains in psoriasis or RA. Theravance Biopharma's $929M deal with Zymeworks — where the upfront equals the total deal value — signals extreme conviction in a validated asset rather than a milestone-laden option structure. That kind of deal architecture tells you the buyer believes the clinical risk is largely retired.

Cross-border deal corridors have opened wide. At least three of the top five deals involve China-originated assets being licensed to global or Japan-based acquirers. Regulatory harmonization through ICH alignment, combined with the maturation of Chinese biotech clinical programs to Phase 2 and beyond, has turned the China-to-global licensing pathway from an opportunistic play into a systematic sourcing strategy. Qyuns Therapeutics' $30M upfront / $780M TDV deal with Caldera and Minghui Pharmaceutical's $110M upfront transaction with ASKA Pharmaceutical both follow this pattern. BD teams that are not running active scouting in Shanghai, Hangzhou, and Suzhou are leaving validated clinical assets on the table.

Notable Deals

LicensorLicenseeUpfrontTDVDate
Qyuns Therapeutics Co., Ltd.Caldera Therapeutics, Inc.$30M$780M2026-11-05
Minghui Pharmaceutical (Hangzhou) LimitedASKA Pharmaceutical Co., Ltd.$110M—2026-11-04
AinosBioPhoenix—$10M2026-09-24
Theravance BiopharmaZymeworks Inc.$929M$929M2026-09-23
Sino BiopharmaceuticalAstraZeneca$200M$2,100M2026-09-23

The Theravance–Zymeworks deal is the outlier that proves the rule. A $929M upfront with zero additional milestones is exceedingly rare in immunology licensing. It tells you Zymeworks saw a de-risked asset — likely Phase 2b data or better — and decided the cost of a milestone structure (delayed payments contingent on events) was higher than the cost of paying full freight upfront to lock out competitors. When buyers start collapsing milestone waterfalls into flat upfronts, you are in a seller's market.

The AstraZeneca–Sino Biopharmaceutical deal is the strategic benchmark. At $200M upfront and $2.1B TDV, the upfront-to-TDV ratio sits at roughly 9.5% — consistent with Deal Benchmarks for late-preclinical to early-clinical immunology assets with global rights. AstraZeneca is not overpaying; it is paying market rate for a high-conviction asset in a space where it needs portfolio depth. BD teams should use this as a reference transaction when structuring comparable deals.

The Ainos–BioPhoenix deal at $10M TDV sits at the opposite end of the spectrum and likely represents an early-stage platform license or regional rights carve-out. Its inclusion in the dataset is a reminder that the 1167% surge is not entirely composed of mega-deals — smaller, preclinical-stage transactions are contributing meaningful volume, suggesting that early-stage immunology assets are finding buyers at a pace not seen since 2021.

What This Means for BD Teams Right Now

If you are selling an immunology asset, this is unambiguously a seller's market. The data says so: 38 transactions competing for finite targets means buyers are moving faster, offering higher upfronts, and compressing diligence timelines. Licensors with Phase 1 or Phase 2 data in hand should be running competitive processes, not bilateral negotiations. The Theravance deal demonstrates that well-run auctions can collapse milestone structures entirely — putting cash in hand rather than on paper.

If you are buying, speed is a competitive advantage. The window to acquire differentiated immunology assets at 2024–2025 pricing is closed. Upfront payments have inflated, and the upfront-to-TDV ratios we are tracking through Solidus show a 2–4 percentage point shift in licensor favor compared to 12 months ago. That does not mean overpay — it means get to term sheet faster. The deals that are closing in Q4 2026 started diligence in Q2. If you are just now initiating outreach, you are competing against signed LOIs.

Deal structure preferences are shifting. Opt-in/opt-out structures that dominated 2023–2024 immunology deals are giving way to committed licenses with higher upfronts and fewer walk-away points. Buyers are signaling commitment because licensors are demanding it — and because the competitive dynamic supports it. Co-development structures are also gaining traction, particularly in deals involving bispecific or multi-target assets where the clinical development plan is complex and both parties benefit from shared risk.

Geographic rights are fragmenting. The ASKA–Minghui deal (Japan-focused) and the prevalence of China-originating assets suggest that regional rights carve-outs are increasingly common. BD teams should model scenarios where global rights are not available and evaluate whether regional economics — particularly Japan, Greater China, and MENA — justify standalone transactions.

Benchmark your next immunology deal against current market rates using the Ambrosia calculator. The difference between a well-benchmarked term sheet and a generic one is 15–30% on upfront value — and in a 38-deal market, that gap compounds fast.

More from the Blog

Deal Intelligence

Ready to Benchmark Your Deal?

Get instant, data-driven deal terms powered by 1,400+ verified biopharma transactions across 12 therapeutic areas.